高危肌层浸润性膀胱癌根治性膀胱切除术后的辅助全身治疗:当前选择与未来机会
本文通过一例71岁局部晚期肌层浸润性膀胱癌合并III期慢性肾病女性病例,讨论根治性膀胱切除术后高危患者辅助化疗的挑战,尤其对顺铂不适合者。近期辅助免疫治疗试验数据显示该亚组有无病生存优势,文章讨论了免疫肿瘤药物在当前和未来的作用。
要点
- 高危肌层浸润性膀胱癌根治术后辅助化疗对顺铂不适合患者存在挑战
- 辅助免疫治疗试验显示该亚组无病生存优势
- 生物标志物和影像评估可能优化未来患者选择
核心结论
- 高危局部晚期膀胱癌根治术后辅助化疗面临挑战,尤其对顺铂不适合者。
- 近期辅助免疫治疗试验提示该亚组有无病生存优势。
研究设计与样本
- 病例报告:71岁女性,局部晚期肌层浸润性膀胱癌,因左肾梗阻无功能致III期慢性肾病。
- 新辅助免疫治疗因肾功能急性恶化停止,随后行根治性膀胱切除术,病理为pT3aN1尿路上皮癌。
主要发现
- 新辅助免疫治疗因肾功能急性恶化而中止。
- 根治性膀胱切除术后病理显示pT3aN1尿路上皮癌。
- 辅助免疫治疗试验数据提示该亚组无病生存优势。
临床怎么用
- 对顺铂不适合的高危患者,辅助免疫治疗可能提供无病生存获益。
- 生物标志物检测和影像评估尿路功能可能有助于优化患者选择。
局限性
- 本文为病例报告及讨论,证据级别有限。
- 辅助免疫治疗的最佳患者选择尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We describe the case of a 71-yr-old woman with locally advanced muscle-invasive bladder cancer and stage III chronic kidney disease due to an obstructed nonfunctional left kidney. She was started on neoadjuvant immunotherapy, but had to stop treatment because of acute worsening of renal function. Radical cystectomy was then performed uneventfully, revealing pT3aN1 urothelial carcinoma of the bladder. Adjuvant chemotherapy in high-risk locally advanced bladder cancer after radical cystectomy currently poses several challenges, especially for cisplatin-ineligible candidates. Recent data on adjuvant immunotherapy trials suggest a disease-free survival advantage for this subgroup of patients. The current and future role of immuno-oncology agents in this setting is discussed. PATIENT SUMMARY: Patients with advanced bladder cancer might benefit from further chemotherapy or immunotherapy following bladder removal, but it is still unclear which patients benefit the most from this strategy. Measurement of biomarkers and scans to show urinary function will probably help in optimising patient selection for this treatment in the near future.
引用
- Mir MC, Campi R, Loriot Y, et al. Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities. Eur Urol Oncol. 2021. PMID: 33967013. doi:10.1016/j.euo.2021.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。